P53-INDEPENDENT APOPTOSIS DURING MAMMARY-TUMOR PROGRESSION IN C3(1) SV40 LARGE T-ANTIGEN TRANSGENIC MICE - SUPPRESSION OF APOPTOSIS DURING THE TRANSITION FROM PRENEOPLASIA TO CARCINOMA/
Ma. Shibata et al., P53-INDEPENDENT APOPTOSIS DURING MAMMARY-TUMOR PROGRESSION IN C3(1) SV40 LARGE T-ANTIGEN TRANSGENIC MICE - SUPPRESSION OF APOPTOSIS DURING THE TRANSITION FROM PRENEOPLASIA TO CARCINOMA/, Cancer research, 56(13), 1996, pp. 2998-3003
Alterations in apoptosis and associated mechanisms during mammary tumo
r progression were investigated in transgenic mice expressing the SV40
large T antigen (T-AG) driven by the rat prostatic steroid-binding pr
otein C3(1) 5'-flanking region. Apoptosis levels, assessed by in situ
end labeling, were low in normal mammary epithelial cells, highest in
atypical hyperplasias (preneoplastic lesions), and less pronounced in
adenocarcinomas. Preneoplastic cells maintain the ability to undergo a
poptosis as a mechanism of tumor growth suppression, but this critical
control of apoptosis is lost as these lesions progress to carcinomas.
These alterations in apoptosis occur during mammary tumor progression
in mice containing wild-type p53(+/+) genotype as well as in mice wit
h the p53(-/-) genotype. Thus, apoptosis in this tumor model occurs th
rough a p53-independent mechanism. Because other studies have demonstr
ated p53-dependent apoptosis in T-AG-induced choroid plexus tumors of
transgenic mice, we propose that the role of p53 in apoptosis may be t
issue-specific. In addition, bcl-2 protein was not expressed in any ma
mmary lesions. SV40 T-AG expression, which correlated with the nuclear
p53 protein at all stages of tumor progression, was low in normal mam
mary epithelial cells, moderately high in atypical hyperplasias, and s
trongly expressed in adenocarcinomas. No p53 mutations were found at a
ny stage of mammary adenocarcinoma development, suggesting that tumor
progression does not require a dominantly acting p53 mutation in this
transgenic model. p21(Waf1/Cip1) a cyclin-dependent kinase inhibitor,
was expressed in normal mammary tissue but was not detected in the mam
mary carcinomas, despite high nuclear accumulation of wild-type p53 pr
otein, suggesting functional loss of p53 due to binding of SV40 T-AG t
o p53. These findings suggest that suppression of apoptosis during the
transition from atypical hyperplasia to adenocarcinoma appears to be
a critical event for mammary cancer development in C3(1)/T-AG transgen
ic mice and occurs by p53- and bcl-2-independent pathways.